|Institutional Source||Beutler Lab|
|Gene Name||UDP-glucose ceramide glucosyltransferase|
|Synonyms||Epcs21, Ugcgl, GlcT-1|
|Is this an essential gene?||Essential (E-score: 1.000)|
|Stock #||R3771 (G1)|
|Chromosomal Location||59189257-59222833 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||T to C at 59189690 bp|
|Amino Acid Change||Phenylalanine to Serine at position 16 (F16S)|
|Ref Sequence||ENSEMBL: ENSMUSP00000030074 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000030074]|
|Predicted Effect||probably benign
AA Change: F16S
PolyPhen 2 Score 0.000 (Sensitivity: 1.00; Specificity: 0.00)
AA Change: F16S
|Predicted Effect||noncoding transcript
|Meta Mutation Damage Score||0.0664|
|Coding Region Coverage||
|Validation Efficiency||99% (69/70)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes an enzyme that catalyzes the first glycosylation step in the biosynthesis of glycosphingolipids, which are membrane components containing lipid and sugar moieties. The product of this reaction is glucosylceramide, which is the core structure of many glycosphingolipids. [provided by RefSeq, Dec 2014]
PHENOTYPE: At embryonic day 7.5, embryos homozygous for a null mutation exhibit decreased size, markedly reduced extraembryonic tissues and a large increase in cells undergoing apoptosis. Mutants die by embryonic day 8.5. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Ugcg||
(F):5'- CGCATCGTGCCGGGATTC -3'
(R):5'- CCAAGGAGACCGATTTAGGGG -3'
(F):5'- AGCCCAAGGGTCTGGAC -3'
(R):5'- GGCCGTTTGGGGATCAGC -3'